Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Double-Blind, Placebo-controlled, Phase III Study to Assess the Efficacy and Safety of KN046 Combined With Platinum-containing Chemotherapy Versus Placebo Combined With Platinum-containing Chemotherapy in First Line Advanced Squamous Non-small Cell Lung Cancer Subjects (ENREACH-L-01)

NCT04474119 is registered in ClinicalTrials.gov with Jiangsu Alphamab Biopharmaceuticals Co., Ltd as lead sponsor.

NCT NCT04474119
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04474119 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Double-Blind, Placebo-controlled, Phase III Study to Assess the Efficacy and Safety of KN046 Combined With Platinum-containing Chemotherapy Versus Placebo Combined With Platinum-containing Chemotherapy in First Line Advanced Squamous Non-small Cell Lung Cancer Subjects (ENREACH-L-01)
Lead sponsor
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Phase
Phase 3
Overall status
Unknown status
Start date
September 14, 2020
Completion date
August 30, 2023
Enrollment
482 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

squamous non-small-cell lung cancer